[Consensus and controversy in the treatment of ischemic cerebrovascular diseases].
Nobuyuki Sakai(Shizuoka City Shimizu Hospital), Haruhiko Kikuchi(Kyoto University), Chiaki Sakai(Kobe City Medical Center General Hospital), Manabu Sakaguchi(Osaka Prefectural Medical Center), Hideyuki Ishihara(Ihara Chemical Industry (Japan)), Satoshi Nakao, Asuka Morizane(Kobe City Medical Center General Hospital), Makoto Takano, Terumasa Kuroiwa
PubMed
November 1, 2004
Cited by 0
Related Papers
C-Reactive Protein Is an Independent Predictor of the Rate of Increase in Early Carotid Atherosclerosis
|Circulation|2001|216
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial
|The Lancet Neurology|2019|216
Global impact of COVID-19 on stroke care
|International Journal of Stroke|2021|151